Abstract
Comparative cell transfer experiments have revealed that, despite their equal immune deficiency, C3H/SCID mice were markedly inferior compared with C.B-17/SCID mice in their ability to accept allogeneic and xenogeneic grafts. Allogeneic C.B-17/SCID bone marrow cells were engrafted poorly compared with syngeneic C3H/SCID when transplanted into C3H/SCID recipients, whereas cells of both strains were equally well engrafted into C.B-17/SCID mice. C.B-17/SCID mice were much more permissive for outgrowth of human Burkitt lymphoma (Raji), as well as for Epstein-Barr virus lymphoma development after transplantation of human peripheral blood lymphocytes. Human skin grafts were accepted by the C.B-17/SCID mice but were promptly rejected by the C3H/SCID mice. The resistance to human RaJi cells could be adoptively transferred by infusion of C3H/SCID splenocytes into C.B-17/SCID mice. Because the C.B-17/SCID and C3H/SCID mice equally lack both T and B lymphocytes, the latter may provide a relevant model for studies of non-T mechanisms of allograft or xenograft rejection.
References
Jun 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·Y ReisnerN Sharon
Sep 1, 1977·European Journal of Immunology·R KiesslingG Cudkowicz
Jan 1, 1992·Annual Review of Immunology·Y Y YuM Bennett
Jan 1, 1989·Advances in Immunology·G Trinchieri
Sep 15, 1988·Nature·D E MosierD B Wilson
Aug 12, 1988·Cell·B A MalynnF W Alt
Mar 1, 1988·The Journal of Experimental Medicine·G C BosmaM J Bosma
Jun 10, 1986·Journal of Immunological Methods·E BaharavI R Cohen
Apr 1, 1987·The Journal of Experimental Medicine·W J MurphyM Bennett
Nov 27, 1986·The New England Journal of Medicine·S C Vlay
Dec 28, 1968·Lancet·R A GattiR A Good
Feb 7, 1981·Lancet·P N TrewbyR S Elkeles
Aug 15, 1981·Lancet·Y ReisnerR J O'Reilly
Feb 10, 1983·Nature·G C BosmaM J Bosma
Jan 1, 1994·Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology·P L PollockM I Luster